Enoxaparin vs Tinzaparin or Dalteparin in cancer patients with VTE
The #RIETEregistry experience appearing soon in RPTH
@mmonrealriete.bsky.social
PI of the #RIETEregistry
Enoxaparin vs Tinzaparin or Dalteparin in cancer patients with VTE
The #RIETEregistry experience appearing soon in RPTH
Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions | @jaccjournals.bsky.social www.jacc.org/doi/10.1016/...
29.09.2025 16:31 β π 2 π 1 π¬ 0 π 0Find it here: www.nature.com/articles/s41...
25.09.2025 20:32 β π 1 π 1 π¬ 0 π 1Identifying PE patients at increased risk for CTEPH
A new #RIETEregistry study
Thanks, Stephan and team
The VTE-PREDICT SCORE, externally validated using data from the #RIETEregistry
Congratulations, Tim and team!
Impact of cancer site on outcomes in patients with acute VTE
The #RIETEregistry experience
In patients with cancer-associated VTE, 90-day outcomes largely vary according to cancer sites
Another #RIETEregistry study appearing soon in JACC Advances
Your 5 minute read for today π€ @mmonrealriete.bsky.social
pubmed.ncbi.nlm.nih.gov/28120516/
Prognostic value of baseline PaCO2 levels on outcome in acute pulmonary embolism
A new #RIETEregistry study appearing soon in Arch Bronconeumol
Interesting data on influence of race from the RIETE registry. After correction for treatment etc, these differences did not show in multi-variate analysis.
#ISTH2025
Must do better for #PE risk stratification. In an @escardio.bsky.social
#EHJ paper we show that a multimarker calculatorπ‘οΈoutperforms the ESC model. Great leadership by
#DavidJimenez @mmonrealriete.bsky.social
#RIETE! π:
tinyurl.com/trpmzbrd